(+)-Erinacin A

(+)-Erinacin A (Erinacine A) is a cyanoditerpenoid isolated from Hericium erinaceus with anticancer, anti-inflammatory and neuroprotective activities. (+)-Erinacin A can induce cancer cell death by activating extrinsic and intrinsic apoptosis pathways. (+)-Erinacin A can also inhibit the expression of NO synthase (iNOS) and the production of nitrotyrosine to exert inflammatory and neuroprotective effects, thereby reducing ischemic brain damage[1][2][3][4][5].

[1]Bailly C, et.al. Erinacine A and related cyathane diterpenoids: Molecular diversity and mechanisms underlying their neuroprotection and anticancer activities. Pharmacol Res. 2020 Sep;159:104953.|[2]Tsai-Teng T, et al. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer’s disease-related pathologies in APPswe/PS1dE9 transgenic mice[J]. Journal of biomedical science, 2016, 23: 1-12.|[3]Prasher P, et al. Key oncologic pathways inhibited by Erinacine A: a perspective for its development as an anticancer molecule[J]. Biomedicine & Pharmacotherapy, 2023, 160: 114332.|[4]Lee K F, et al. Protective effects of Hericium erinaceus mycelium and its isolated erinacine A against ischemia-injury-induced neuronal cell death via the inhibition of iNOS/p38 MAPK and nitrotyrosine[J]. International journal of molecular sciences, 2014, 15(9): 15073-15089.|[5]Lee K C, et al. Induction apoptosis of erinacine A in human colorectal cancer cells involving the expression of TNFR, Fas, and Fas ligand via the JNK/p300/p50 signaling pathway with histone acetylation[J]. Frontiers in Pharmacology, 2019, 10: 1174.